Societe de Promotion Pharmaceutique du Maghreb S.A.
Price History & Performance
|Historical stock prices|
|Current Share Price||د.م1,170.00|
|52 Week High||د.م690.00|
|52 Week Low||د.م1,180.00|
|1 Month Change||0%|
|3 Month Change||26.08%|
|1 Year Change||61.60%|
|3 Year Change||15.84%|
|5 Year Change||6.46%|
|Change since IPO||19.75%|
Recent News & Updates
|PRO||MA Pharmaceuticals||MA Market|
Return vs Industry: PRO underperformed the MA Pharmaceuticals industry which returned 87.5% over the past year.
Return vs Market: PRO exceeded the MA Market which returned 26.4% over the past year.
Stable Share Price: Insufficient data to determine PRO's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine PRO's volatility change over the past year.
About the Company
|1947||n/a||Ma'mon Salameh Alaraideh||https://www.promopharm.co.ma|
Societe de Promotion Pharmaceutique du Maghreb S.A. produces, commercializes, imports, and exports medicines, derma-pharmaceuticals, and cosmetic products in Africa. It also subcontracts medicines for national and international laboratories. The company was founded in 1947 and is headquartered in Had-Soualem, Morocco.
Societe de Promotion Pharmaceutique du Maghreb Fundamentals Summary
|PRO fundamental statistics|
Is PRO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PRO income statement (TTM)|
|Cost of Revenue||د.م272.81m|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||60.26|
|Net Profit Margin||10.51%|
How did PRO perform over the long term?See historical performance and comparison
Is Societe de Promotion Pharmaceutique du Maghreb undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PRO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PRO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PRO is poor value based on its PE Ratio (19.4x) compared to the African Pharmaceuticals industry average (9.4x).
PE vs Market: PRO is good value based on its PE Ratio (19.4x) compared to the MA market (26.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRO is overvalued based on its PB Ratio (3x) compared to the XF Pharmaceuticals industry average (1.6x).
How is Societe de Promotion Pharmaceutique du Maghreb forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Societe de Promotion Pharmaceutique du Maghreb has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Societe de Promotion Pharmaceutique du Maghreb performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRO has high quality earnings.
Growing Profit Margin: PRO's current net profit margins (10.5%) are higher than last year (10%).
Past Earnings Growth Analysis
Earnings Trend: PRO's earnings have declined by 14.5% per year over the past 5 years.
Accelerating Growth: PRO's earnings growth over the past year (15.7%) exceeds its 5-year average (-14.5% per year).
Earnings vs Industry: PRO earnings growth over the past year (15.7%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: PRO's Return on Equity (15.7%) is considered low.
How is Societe de Promotion Pharmaceutique du Maghreb's financial position?
Financial Position Analysis
Short Term Liabilities: PRO's short term assets (MAD451.8M) exceed its short term liabilities (MAD151.0M).
Long Term Liabilities: PRO's short term assets (MAD451.8M) exceed its long term liabilities (MAD9.5M).
Debt to Equity History and Analysis
Debt Level: PRO's debt to equity ratio (0%) is considered satisfactory.
Reducing Debt: PRO's debt to equity ratio has reduced from 0.09% to 0% over the past 5 years.
Debt Coverage: Insufficient data to determine if PRO's debt is well covered by operating cash flow.
Interest Coverage: PRO earns more interest than it pays, so coverage of interest payments is not a concern.
What is Societe de Promotion Pharmaceutique du Maghreb current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PRO is not paying a notable dividend for the MA market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRO's dividend in 3 years as they are not forecast to pay a notable one for the MA market.
How experienced are the management team and are they aligned to shareholders interests?
Ma'mon Salameh Alaraideh
Mr. Ma'mon Salameh Muhaisen Alaraideh serves as Chief Executive Officer at Societe de Promotion Pharmaceutique du Maghreb S.A. and serves as its Director.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Societe de Promotion Pharmaceutique du Maghreb S.A.'s employee growth, exchange listings and data sources
- Name: Societe de Promotion Pharmaceutique du Maghreb S.A.
- Ticker: PRO
- Exchange: CBSE
- Founded: 1947
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: د.م1.170b
- Shares outstanding: 1.00m
- Website: https://www.promopharm.co.ma
Number of Employees
- Societe de Promotion Pharmaceutique du Maghreb S.A.
- Rue 7, zone industrielle du Sahel
- BP 96/97
- 26 400
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 16:30|
|End of Day Share Price||2021/10/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.